Key result
Current pharmacological therapies for acute heart failure have significant limitations and adverse effects, highlighting the need for properly designed trials of new and emerging agents.
Why the study?
The study was conducted to present an overview of current approaches to the pharmacological therapy of acute heart failure.
Answers are grounded in this paper and cite their sources.
This review highlights the limitations of current acute heart failure therapies and emphasizes the need for new pharmacological agents and appropriately designed clinical trials.
The objective : to present an overview of current approaches to pharmacological therapy of acute heart failure ( AHF ). Results : the discussion focuses on drugs that are currently available and being actively studied in ongoing clinical trials. Disadvantages and adverse reactions of modern medications for the treatment of AHF are presented. Vasodilators cannot be used for arterial hypotension; inotropic drugs (catecholamines and phosphodiesterase inhibitors) produce proarrhythmogenic effect, increase the myocardial oxygen demand, and may cause excessive vasodilation. The mortality in patients receiving these medications and vasopressor agents remains high. The article presents data on the positive hemodynamic effect of levosimendan calcium sensitizer in patients with severe heart failure, as well as in some other categories of cardiac surgery patients but it emphasizes that the attitude to its effect on lon g-t erm survival of patients remains ambiguous. To remove contradictions, it is necessary to conduct the trial that is properly designed and does not contradict the indications and contraindications noted in the instructions for its use. It is suggested that in such trials, in particular, it is advisable to use temporary endpoints of the trial that are comparable to the duration of action of the studied drugs. In the nearest future, data will be obtained that will allow evaluating the possibility of wide clinical use of new groups of drugs: cardiac myosin activators, natriuretic peptides, vasopressin receptor inhibitors, drugs that affect the expression of calcium ATP ase in the cardiac sarcoplasmic network ( SERCA 2a), including those developed using genetically engineered technologies.
No takes yet. Share an insight, caveat, or question.
А. А. Еременко (2020) conducted a review in Acute heart failure. Pharmacological therapy was evaluated. Current pharmacological therapies for acute heart failure have significant limitations and adverse effects, highlighting the need for properly designed trials of new and emerging agents.
Synapse has enriched 10 related papers. Consider them for comparative context: